4.3 Hepatic Blood Flow, Metabolism, and Clearance

4.3 Hepatic Blood Flow, Metabolism, and Clearance

The liver is the primary metabolic clearinghouse for anaesthetic drugs, the source of essential circulating proteins, and the central regulator of intermediary metabolism. Thorough comprehension of hepatic vascular anatomy, autoregulatory buffering, biotransformation pathways, and pharmacokinetic models of clearance is required for safe perioperative patient care.

---

1. Dual Hepatic Microcirculation and Oxygenation

Dual Vascular Architecture

Total hepatic blood flow ($Q_H$) averages 1.5 L/min in an adult (~100 mL/100g/min of liver tissue), representing 25% of resting cardiac output:

• Portal Vein (~75% of flow, ~1100 mL/min): Formed by the confluence of the splenic vein and superior mesenteric vein, draining the venous outflow of the gastrointestinal tract, spleen, and pancreas. It is a low-pressure system (7 to 10 mmHg). Although venous, it supplies 50% of the liver's total oxygen supply due to its sheer volume. Oxygen saturation is intermediate ($S_{pv}\text{O}_2 \approx 65\text{--}75\%$ in the fasting state, dropping to ~45–50% during active digestion). Portal flow is largely passive and lacks intrinsic autoregulation; it depends on upstream splanchnic arteriolar tone and post-sinusoidal resistance.
• Hepatic Artery (~25% of flow, ~400 mL/min): Originates from the celiac axis via the common hepatic artery. It is a high-pressure system (mean pressure matches systemic MAP ~90 mmHg) delivering fully oxygenated blood ($S_a\text{O}_2 \approx 98\%$), providing the remaining 50% of hepatic oxygen delivery. The hepatic artery possesses muscular walls with active autoregulatory and autonomic control.

                    Dual Hepatic Inflow
           Portal Vein (75%)     Hepatic Artery (25%)
           ~1100 mL/min, 7-10 mmHg  ~400 mL/min, MAP ~90 mmHg
           50% of O2 Delivery       50% of O2 Delivery
                     \                  /
                      \                /
                       v              v
                     Hepatic Sinusoids (2-4 mmHg)
                     - Low pressure, fenestrated
                     - Space of Disse (exchange)
                                |
                                v
                         Central Veins
                                |
                                v
                         Hepatic Veins
                                |
                                v
                    Inferior Vena Cava (IVC)

Sinusoidal Microcirculation

Within the microscopic liver lobules and acini:

• Branches of the portal venules and hepatic arterioles merge at the periphery of the hepatic lobule to discharge mixed blood into the hepatic sinusoids.
• Sinusoids are low-pressure channels (2 to 4 mmHg) that direct blood centripetally past plates of hepatocytes toward the central lobular vein.
• Discontinuous endothelial lining: Sinusoidal endothelial cells possess large fenestrations (100–200 nm) and lack a basement membrane. Plasma filters freely into the space of Disse (the perisinusoidal space separating endothelial cells from hepatocyte microvilli), allowing direct, unhindered contact between plasma proteins, drugs, and hepatocytes.
• Reticuloendothelial system: Kupffer cells (tissue-resident macrophages) anchor within the sinusoidal lumen, phagocytosing bacteria, endotoxins, and cellular debris cleared from the splanchnic circulation.

---

2. The Hepatic Arterial Buffer Response (HABR)

Because portal venous blood flow is dictated by the metabolic and digestive activity of upstream gastrointestinal organs, the liver cannot regulate portal inflow. To protect hepatic oxygenation from sudden reductions in portal flow, the liver possesses an intrinsic, compensatory vascular mechanism known as the Hepatic Arterial Buffer Response (HABR).

The Adenosine Washout Mechanism

The HABR is explained by the adenosine washout hypothesis:

1. Adenosine is an endogenous vasodilator synthesized and secreted at a constant basal rate into the interstitial fluid surrounding the terminal microvessels in the periportal space of Mall.
2. When portal venous blood flow is normal or high, adenosine is continuously washed away into the sinusoids, keeping local periportal adenosine concentrations low.
3. If portal venous flow decreases (e.g., during splanchnic vasoconstriction, hemorrhage, systemic hypotension, or mesenteric traction), the washout rate of adenosine declines.
4. Local adenosine accumulates in the space of Mall and binds to vascular $A_2$ purinergic receptors on adjacent hepatic arterioles.
5. Activation of $A_2$ receptors stimulates adenylyl cyclase, elevating cAMP and opening potassium channels, which induces profound hepatic arterial vasodilation.
6. Hepatic arterial flow increases, restoring up to 60% of the lost total hepatic blood flow and defending hepatic oxygenation.

Strict Unidirectionality: A Crucial Clinical Vulnerability

The HABR is strictly unidirectional:

• While reductions in portal flow trigger hepatic arterial dilatation, reductions in hepatic arterial flow do not produce any reciprocal increase in portal venous flow.
• If hepatic arterial flow is compromised (e.g., accidental ligation during cholecystectomy or transplantation, or severe shock), the portal vein cannot compensate, and acute hepatocellular ischemia ensues.

---

3. Perioperative and Anaesthetic Influences on Hepatic Perfusion

---

4. Pharmacokinetic Models of Hepatic Drug Clearance

Total hepatic clearance ($CL_H$) represents the volume of blood completely cleared of drug by the liver per unit of time:

$CL_H = Q_H \times E_H$

Where $Q_H$ is total hepatic blood flow (~1.5 L/min) and $E_H$ is the hepatic extraction ratio:

$E_H = \frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}} = \frac{f_u \times CL_{\text{int}}}{Q_H + (f_u \times CL_{\text{int}})}$

Where $CL_{\text{int}}$ is the intrinsic clearance (the intrinsic enzymatic and biliary transport capacity of hepatocytes) and $f_u$ is the unbound (free) drug fraction in plasma.

High vs Low Extraction Ratio Drugs

   High Extraction Drugs (E > 0.7)            Low Extraction Drugs (E < 0.3)
   ==============================            =============================
   Rate-limiting step: BLOOD FLOW            Rate-limiting step: ENZYME CAPACITY
   - Flow-limited (perfusion-dependent)      - Capacity-limited (enzyme-dependent)
   - CL_H ≈ Q_H                              - CL_H ≈ f_u × CL_int
   - Sensitive to: Cardiac output, PEEP      - Sensitive to: Cirrhosis, CYP induction
   - Examples: Propofol, Lidocaine, Morphine - Examples: Diazepam, Rocuronium, Warfarin

High Extraction Ratio Drugs ($E_H > 0.7$)

• Pharmacological Behavior: Hepatocytes metabolize the drug so rapidly and efficiently that intrinsic clearance far exceeds liver blood flow ($f_u \times CL_{\text{int}} \gg Q_H$). Thus, the mathematical denominator simplifies, yielding:

$CL_H \approx Q_H$

• Rate-Limiting Factor: Delivery of drug to the liver (perfusion-dependent or flow-limited clearance).
• Key Examples: Propofol, lidocaine, morphine, fentanyl, sufentanil, ketamine, propranolol, nitroglycerin.
• Clinical Implications: Changes in hepatic blood flow (e.g., heart failure, shock, hemorrhage, high PEEP, beta-blockade) directly dictate clearance. A 50% drop in cardiac output halves propofol clearance, leading to drug accumulation. In contrast, displacement from plasma protein binding or mild enzyme induction has minimal impact on systemic clearance. These drugs undergo extensive first-pass metabolism, resulting in poor oral bioavailability.

Low Extraction Ratio Drugs ($E_H < 0.3$)

• Pharmacological Behavior: Hepatocyte metabolic capacity is the rate-limiting step; organ blood flow far exceeds the ability of enzymes to clear the drug ($Q_H \gg f_u \times CL_{\text{int}}$). Thus:

$CL_H \approx f_u \times CL_{\text{int}}$

• Rate-Limiting Factor: Intrinsic microsomal enzyme activity and free unbound drug fraction (capacity-limited or enzyme-dependent clearance).
• Key Examples: Diazepam, lorazepam, alfentanil, rocuronium, vecuronium, methohexital, phenytoin, warfarin, theophylline.
• Clinical Implications: Fluctuations in liver blood flow have virtually no effect on clearance. Clearance is profoundly impaired by liver cirrhosis, hypothermia, acute hepatitis, and CYP enzyme inhibition. Alterations in plasma protein binding (e.g., hypoalbuminemia) alter the free fraction ($f_u$), dramatically shifting active unbound drug concentrations.

Intermediate Extraction Ratio Drugs ($E_H = 0.3\text{ to } 0.7$)

• Examples: Midazolam, methadone, codeine.
• Behavior: Clearance is sensitive to both hepatic blood flow and intrinsic enzymatic activity.

---

5. Pathways of Biotransformation: Phase I and Phase II Reactions

Biotransformation converts lipophilic, non-polar drugs into hydrophilic, polar metabolites suitable for excretion in bile or urine.

Phase I Reactions: Functionalization

• Chemical reactions: Oxidation, reduction, and hydrolysis. Introduces or unmasks a polar functional group (e.g., $-OH$, $-NH_2$, $-SH$, $-COOH$). Metabolites may be inactive, less active, or occasionally more potent or toxic than the parent compound.
• Cytochrome P450 (CYP) hemoproteins: Superfamily of membrane-bound enzymes located in the smooth endoplasmic reticulum (microsomes) of hepatocytes. They utilize molecular oxygen and electrons donated from NADPH via NADPH-CYP oxidoreductase: $\text{Drug} + O_2 + \text{NADPH} + H^+ \xrightarrow{\text{CYP}} \text{Drug-OH} + H_2O + \text{NADP}^+$
• Major CYP Isoforms in Anaesthesia:
  1. CYP3A4/5 (~50% of all clinical drugs): Metabolizes fentanyl, sufentanil, alfentanil, midazolam, lidocaine, bupivacaine, dexmedetomidine, and calcium channel blockers. Inhibitors: azole antifungals, erythromycin, ciprofloxacin, cimetidine, grapefruit juice. Inducers: rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort.
  2. CYP2D6: Responsible for the metabolic activation of opioid prodrugs: bioactivation of codeine to morphine and tramadol to O-desmethyltramadol (M1). Also clears ondansetron and metoprolol. Exhibits profound genetic polymorphism: poor metabolizers experience no analgesia from codeine or tramadol, whereas ultrarapid metabolizers (gene duplication) risk fatal respiratory depression from standard codeine doses.
  3. CYP2E1: Metabolizes volatile inhalational agents (halothane, isoflurane, sevoflurane) and paracetamol (acetaminophen). Induced by chronic ethanol intake. Halothane oxidation generates reactive trifluoroacetyl chloride, which acetylates hepatocyte surface proteins, eliciting immune-mediated halothane hepatitis.
• Non-Microsomal and Extrahepatic Phase I Mechanisms:
  • Plasma pseudocholinesterase (butyrylcholinesterase): Synthesized in the liver; hydrolyzes succinylcholine and mivacurium.
  • Non-specific tissue and blood esterases: Clear remifentanil and esmolol, resulting in ultra-short context-sensitive half-times independent of hepatic or renal function.
  • Hofmann elimination: Spontaneous, non-enzymatic chemical breakdown of atracurium and cisatracurium at normal physiological pH and temperature.

Phase II Reactions: Conjugation

• Mechanism: Covalent attachment of an endogenous, highly polar, hydrophilic substrate to a functional group on the parent drug or its Phase I metabolite. Phase II reactions almost universally yield inactive, non-toxic, water-soluble products excreted by the kidneys or biliary tract.
• Glucuronidation (UDP-glucuronosyltransferases, UGT): Most prevalent conjugation pathway. Transfers glucuronic acid from UDP-glucuronic acid to substrates. Clears propofol, morphine, and paracetamol. Morphine is converted mainly into morphine-3-glucuronide (M3G, roughly 55–75%), which has no analgesic activity and may be neuroexcitatory, and morphine-6-glucuronide (M6G, about 10%), a $\mu$-agonist more potent than morphine that accumulates in renal failure.
• Sulfation (sulfotransferases, SULT): Cytosolic pathway conjugating sulfate.
• Acetylation (N-acetyltransferases, NAT1/NAT2): Clears hydralazine, procainamide, and isoniazid. Polymorphism produces "slow acetylators" prone to drug-induced lupus.
• Glutathione Conjugation (Glutathione S-transferase, GST): Essential detoxifying pathway. Neutralizes the toxic, electrophilic Phase I metabolite of paracetamol, NAPQI (N-acetyl-p-benzoquinone imine). In paracetamol overdose, hepatic glutathione stores are depleted (>70%); excess NAPQI binds to hepatocyte mitochondrial proteins, causing centrilobular necrosis. Treatment with N-acetylcysteine (NAC) restores intracellular glutathione synthesis.

---

6. Synthetic and Coagulation Functions of the Liver

Plasma Protein Synthesis

• Albumin: Synthesized exclusively by hepatocytes at 12 to 15 g/day (half-life: 20 days). Maintains 75–80% of plasma oncotic pressure and binds acidic drugs (thiopental, propofol, phenytoin, warfarin). Due to its long half-life, albumin is a marker of chronic, rather than acute, hepatic dysfunction.
• Alpha-1 Acid Glycoprotein (AAG): Acute-phase reactant that binds basic drugs (local anaesthetics, opioids). Serum concentrations rise acutely during inflammation, surgical trauma, and sepsis, lowering the free unbound fraction of local anaesthetics and reducing the risk of systemic toxicity (LAST).

Coagulation Factor Synthesis: The Factor VIII Exception

The liver synthesizes almost all circulating procoagulant and anticoagulant proteins:

• Procoagulants: Fibrinogen (I), Prothrombin (II), Factor V, Factor VII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII.
• Vitamin K-dependent factors: Factors II, VII, IX, and X, along with anticoagulant proteins C and S. They require post-translational $\gamma$-carboxylation of glutamic acid residues catalyzed by vitamin K-dependent carboxylase.
• Natural Anticoagulants: Antithrombin III, Protein C, Protein S.
• The Critical EDAIC Exception: Factor VIII and von Willebrand factor (vWF) are NOT synthesized by hepatocytes! They are synthesized and released by vascular endothelial cells throughout the body and sinusoidal endothelial cells. In severe acute liver failure or advanced cirrhosis, Factor VIII levels are characteristically normal or elevated (due to acute-phase endothelial release). If Factor VIII is depleted, disseminated intravascular coagulation (DIC) or a primary hematologic disorder must be suspected.
• Diagnostic Sensitivity: Factor VII has the shortest biological half-life of any clotting factor (4 to 6 hours). Consequently, prothrombin time (PT) and International Normalized Ratio (INR) are the most sensitive laboratory markers of acute hepatocellular failure.